You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

HER2-Mutated Metastatic Non-Small Cell Lung Cancer: Key Pearls for Your Practice 

  • Authors: Fred Hirsch, MD, PhD; Enriqueta Felip, MD, PhD; Stephen Liu, MD
  • CME / ABIM MOC Released: 10/14/2022
  • Valid for credit through: 10/14/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, pulmonologists, pathologists, and other members of the multidisciplinary care team involved in the care of patients with HER2-mutated metastatic NSCLC.

The goal of this activity is that learners will be better able to understand HER2-mutated metastatic NSCLC and how to optimize the care of these patients as part of the multidisciplinary team. 

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical trial data evaluating therapies for patients with HER2-mutated metastatic NSCLC
  • Have greater competence related to
    • Identifying HER2 mutations in patients with metastatic NSCLC
    • Personalizing care for patients with HER2-mutated metastatic NSCLC
    • Managing adverse events in patients receiving therapy for HER2-mutated metastatic NSCLC


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

-


Faculty

  • Fred Hirsch, MD, PhD

    Professor of Medicine
    Icahn School of Medicine
    Mount Sinai Hospital
    Director
    Center of Excellence for Thoracic Oncology
    Tisch Cancer Institute
    New York, New York, United States

    Disclosures

    Fred Hirsch, MD, PhD, has no relevant financial relationships.

  • Enriqueta Felip, MD, PhD

    Head of Thoracic Oncology Unit
    Vall d'Hebron University Hospital
    Barcelona, Spain

    Disclosures

    Enriqueta Felip, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Eli Lilly; F. Hoffmann-La Roche; GlaxoSmithKline; Janssen; Merck; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Sanofi; Takeda
    Speaker or member of speakers bureau for: AstraZeneca; Bristol-Myers Squibb; Eli Lilly; F. Hoffmann-La Roche; Janssen; Merck; Merck Sharp & Dohme; Pfizer; Sanofi; Takeda; TouchOncology
    Research funding from: Merck Healthcare

  • Stephen Liu, MD

    Associate Professor of Medicine
    Georgetown University
    Director of Thoracic Oncology and Developmental Therapeutics
    Georgetown Lombardi Comprehensive Cancer Center
    Washington, DC, United States

    Disclosures

    Stephen Liu, MD, has the following relevant financial relationships:
    Consultant or advisor for: Amgen; AstraZeneca; Bayer; BeiGene; Blueprint; Boehringer-Ingelheim; Bristol-Myers Squibb; Catalyst; Daiichi Sankyo; Eisai; Elevation Oncology; Genentech/Roche; Gilead; Guardant Health; Janssen; Jazz Pharmaceuticals; Lilly; Merck/MSD; Novartis; Regeneron; Sanofi; Takeda; Turning Point Therapeutics
    Research funding from: Alkermes; Bayer; Blueprint; Bristol-Myers Squibb; Elevation Oncology; Genentech; Gilead; Merck; Merus; Nuvalent; Pfizer; RAPT; Turning Point Therapeutics

Editor

  • Lisa Cockrell, PhD

    Medical Education Director, Medscape, LLC

    Disclosures

    Lisa Cockrell, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Lisa Simani, APRN, MS, ACNP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

HER2-Mutated Metastatic Non-Small Cell Lung Cancer: Key Pearls for Your Practice 

Authors: Fred Hirsch, MD, PhD; Enriqueta Felip, MD, PhD; Stephen Liu, MDFaculty and Disclosures

CME / ABIM MOC Released: 10/14/2022

Valid for credit through: 10/14/2023

processing....